Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): the coming week ...

March 29, 2020

... will provide a test for investors by U.S. econ data being released.  Last week’s brief rebound was subsidized by government stimuli; what’s to support the next depth?  

Regenerative Medicine Earnings Scorecard - Q4/19 - to date

March 17, 2020

A scorecard of earnings of 35 covered  companies (1 more - ATHX of 28 reporting) The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"  

Applied Genetic Technologies Corporation (AGTC) has completed the planned enrollment

March 16, 2020

In all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its P1/2 clinical programs with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. AGTC continues to enroll pediatric patients at the higher dose groups in both trials. The share price was up and the down -$0.17 BUY post disruption or give it a day, maybe 2  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.